OCU410 for geographic atrophy

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Aug 2023: Trial registered, NCT06018558
  2. 27 Oct 2023: Trial started, NCT06018558

The trials

NCT06018558: Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

State
Under way
Phase
Phase 1 and Phase 2
People
60 taking part
Started
27 Oct 2023
Primary completion
3 Feb 2026
Arms
Phase1 Dose Escalation- Low Dose (2.5×10E10 vg/mL):, Phase1 Dose Escalation- Medium Dose (5×10E10 vg/mL):, Phase1 Dose Escalation- High Dose (1.5×10E11 vg/mL):, Phase 2 Dose Expansion: Maximum tolerated dose (MTD) from Phase 1-Randomized Arm, Phase 2 Dose Expansion: Lower Dose from Phase 1-Randomized Arm
Results
None posted
  1. 30 Aug 2023: Trial registered
  2. 27 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.